{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:06:46Z","timestamp":1749874006385,"version":"3.41.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,13]]},"DOI":"10.7759\/cureus.85930","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T16:01:28Z","timestamp":1749830488000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Anti-TIF1\u03b3 Antibody-Positive Dermatomyositis Associated With Malignancy"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Yasir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelnassir","family":"Abdelgabar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Nayeem","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3761","article-title":"The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants","volume":"30","author":"Didona D","year":"2020","unstructured":"Didona D, Juratli HA, Scarsella L, Eming R, Hertl M. The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants. Eur J Dermatol. 2020, 30:229-42. 10.1684\/ejd.2020.3761","journal-title":"Eur J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang JK","year":"2017","unstructured":"Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg. 2017, 21:131-6. 10.1177\/1203475416665601","journal-title":"J Cutan Med Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000245721.02512.77","article-title":"Cancer and myositis: new insights into an old association","volume":"18","author":"Levine SM","year":"2006","unstructured":"Levine SM. Cancer and myositis: new insights into an old association. Curr Opin Rheumatol. 2006, 18:620-4. 10.1097\/01.bor.0000245721.02512.77","journal-title":"Curr Opin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068502","article-title":"The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis","volume":"66","author":"Chinoy H","year":"2007","unstructured":"Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007, 66:1345-9. 10.1136\/ard.2006.068502","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge Z","year":"2016","unstructured":"Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016, 280:8-23. 10.1111\/joim.12451","journal-title":"J Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh NJ","year":"2018","unstructured":"McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018, 14:290-302. 10.1038\/nrrheum.2018.56","journal-title":"Nat Rev Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2020.05.006","article-title":"Risk factors and cancer screening in myositis","volume":"46","author":"Moghadam-Kia S","year":"2020","unstructured":"Moghadam-Kia S, Oddis CV, Ascherman DP, Aggarwal R. Risk factors and cancer screening in myositis. Rheum Dis Clin North Am. 2020, 46:565-76. 10.1016\/j.rdc.2020.05.006","journal-title":"Rheum Dis Clin North Am"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff IN","year":"2006","unstructured":"Targoff IN, Mamyrova G, Trieu EP, et al.. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006, 54:3682-9. 10.1002\/art.22164","journal-title":"Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000641","article-title":"The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome","volume":"31","author":"Lu X","year":"2019","unstructured":"Lu X, Peng Q, Wang G. The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. Curr Opin Rheumatol. 2019, 31:643-9. 10.1097\/BOR.0000000000000641","journal-title":"Curr Opin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197707000-00001","article-title":"Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis","volume":"56","author":"Bohan A","year":"1977","unstructured":"Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977, 56:255-86. 10.1097\/00005792-197707000-00001","journal-title":"Medicine (Baltimore)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14046","article-title":"Risk factors for cancer-associated myositis: A large-scale multicenter cohort study","volume":"24","author":"Li Y","year":"2021","unstructured":"Li Y, Jia X, Sun X, et al.. Risk factors for cancer-associated myositis: A large-scale multicenter cohort study. Int J Rheum Dis. 2021, 24:268-73. 10.1111\/1756-185X.14046","journal-title":"Int J Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill CL","year":"2001","unstructured":"Hill CL, Zhang Y, Sigurgeirsson B, et al.. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001, 357:96-100. 10.1016\/S0140-6736(00)03540-6","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08055.x","article-title":"A systematic review of juvenile-onset clinically amyopathic dermatomyositis","volume":"157","author":"Gerami P","year":"2007","unstructured":"Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007, 157:637-44. 10.1111\/j.1365-2133.2007.08055.x","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5215","article-title":"Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?","volume":"9","author":"Khanna U","year":"2021","unstructured":"Khanna U, Galimberti F, Li Y, Fernandez AP. Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?. Ann Transl Med. 2021, 9:432. 10.21037\/atm-20-5215","journal-title":"Ann Transl Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009639","article-title":"Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts","volume":"97","author":"Leatham H","year":"2018","unstructured":"Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, Fiorentino D. Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018, 97:9639. 10.1097\/MD.0000000000009639","journal-title":"Medicine (Baltimore)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpor.2014.02.005","article-title":"Nasopharyngeal carcinoma in dermatomyositis patients: a 10-year retrospective review in Hospital Selayang, Malaysia","volume":"19","author":"Teoh JW","year":"2014","unstructured":"Teoh JW, Yunus RM, Hassan F, Ghazali N, Abidin ZA. Nasopharyngeal carcinoma in dermatomyositis patients: a 10-year retrospective review in Hospital Selayang, Malaysia. Rep Pract Oncol Radiother. 2014, 19:332-6. 10.1016\/j.rpor.2014.02.005","journal-title":"Rep Pract Oncol Radiother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino DF","year":"2013","unstructured":"Fiorentino DF, Chung LS, Christopher-Stine L, et al.. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3. Arthritis Rheum. 2013, 65:2954-62. 10.1002\/art.38093","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1023\/a:1009568532177","article-title":"TGF-beta signaling in mammary gland development and tumorigenesis","volume":"6","author":"Wakefield LM","year":"2001","unstructured":"Wakefield LM, Piek E, B\u00f6ttinger EP. TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2001, 6:67-82. 10.1023\/a:1009568532177","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1471-y","article-title":"TIF1\u03b3 interferes with TGF\u03b21\/SMAD4 signaling to promote poor outcome in operable breast cancer patients","volume":"15","author":"Kassem L","year":"2015","unstructured":"Kassem L, Deygas M, Fattet L, et al.. TIF1\u03b3 interferes with TGF\u03b21\/SMAD4 signaling to promote poor outcome in operable breast cancer patients. BMC Cancer. 2015, 15:453. 10.1186\/s12885-015-1471-y","journal-title":"BMC Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/374708-a-case-of-anti-tif1-antibody-positive-dermatomyositis-associated-with-malignancy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T16:01:28Z","timestamp":1749830488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/374708-a-case-of-anti-tif1-antibody-positive-dermatomyositis-associated-with-malignancy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.85930","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}